Monday, 16 November 2026SearchArchive
volteface
News

‘Dispenseroo’ tube adverts highlight everything wrong with the UK’s legal medical cannabis model

You may remember the ‘dispensary’ first made itself known in September 2022 when some 2,500 unauthorised adverts were spotted on the London Underground, mimicking the branding of food delivery service Deliveroo. Although many assumed the campaign was a spoof or art project, a simple google search took users to a fully operational website selling legitimate products, such as edibles, vapes and flower. 

At the time the founder of the website, who goes by the pseudonym of ‘S’ gave a number of interviews, boasting that business was effectively booming, turning over around £50,000 a week in sales. 

However, fast forward to December, and it seemed unlikely the cash flow, and Dispenseroo itself, would continue into the future. The food giant announced that they were taking legal action against the start-up for trademark infringement and ‘substantive mimicking’ of the brand.  

Although Dispenseroo effectively disputes any wrongdoing, they have now announced that moving forward they will be rebranding as ‘Dispenseree’, to ‘protect their customers and service’. What’s more, despite describing the situation as ‘David vs Goliath’, business appears to be thriving, with ‘S’ hinting that monthly revenue has now surpassed £1m. 

What does this mean for the medical cannabis market?

Interestingly, ‘S’ has also revealed that a high proportion of their customers are buying their products for medical reasons. Speaking to The Independent, he said: 

“There is a lot of misinformation and negative images to those that are ill-informed. But many of our customers use cannabis for medical reasons and to treat complex illnesses like depression.”

Despite medical cannabis being legal in the UK since 2018, it is currently estimated that around 1.8m people with diagnosed medical conditions are using illicit cannabis to self-medicate, The fact that patients are still turning to the illicit market to access cannabis is emblematic of the wider problems with and barriers to the medical cannabis industry.

One thing that the existence of ‘Dispenseroo’ does make clear is that it is seemingly easier for an entirely illegal ‘dispensary’ to advertise its products to the masses than any legally operating UK clinic, as our Director, Paul North, pointed out on Twitter: 

It is easier for this completely illegal UK cannabis dispensary to advertise its services than legally operating UK clinicshttps://t.co/2BxKL93xMS

— Paul North (@Paul__North) January 3, 2023

Whilst guidelines ultimately exist to protect patients and ensure that companies are operating ‘above board’, they also add to the complexities of the legal market and make it difficult for companies to visibly advertise their products and services to patients. There’s no doubt that this contributes to the fact that nearly 84% of UK residents are still unaware that medical cannabis is legal. 

It is also clear that the medical market, in its current state, is failing to serve patients in the way it should. A number of clinics have recently come under fire for decisions to up their prices, especially considering the current cost-of-living crisis that almost all patients find themselves in. 

In October 2022, Grow Pharma were criticised for their decision to increase prices by 50p per gram on their Open Access Initiative. Patients thought this was interesting considering rumours of such a move within the industry for a while, and the economic climate. 

More recently Lyphe Clinic have come under scrutiny for their controversial decision to withdraw from Project21, removing the NOIDECS cannabis range from the scheme and increasing its price from £5 per gram to £6.50 per gram. Again, the move was criticised for being made at a time of economic hardship, and when disabled individuals are facing increased risk. 

As the legal medical market is increasingly unable to meet the needs of patients, individuals are being forced to turn to illicit supply, feeding the cycle even further. 

As a patient, I just had to cancel my latest clinic swap, because I can’t afford the rising cost of legal medical cannabis.

With Noidecs leaving #ProjectTwenty21, and the only £4.50/g flower out of stock until March, I save nearly £200pm going back to street supply, and have to.

— 🇬🇧 MedBud.wiki (@MedBudCIC) January 10, 2023

 Therefore, it is no surprise that illegal dispensaries such as Dispenseroo are popping up and gaining traction. They clearly take advantage of a range of issues that currently exist within the legal medical market, as Rob Jappie highlighted in a Twitter thread. 

Not only are they able to make their products visible, in some instances they match the prices of medical cannabis, whilst providing a service that’s hassle-free and quick. No worrying about the cost of repeat prescriptions, consultations or the lacklustre service that some clinics have been criticised for providing. 

What’s next?

Well, whilst the medical market continues to face hurdles, Dispenseroo states that they are ready to take their advertising to the ‘next level’ in 2023. In a New Year update they stated they will be hiring more staff, setting up a help centre with a ticket-based support system, increasing the range and quantity of stock and restructuring to drive costs down. If only the legal market would do the same, right? 

Unfortunately, until the medical cannabis industry begins to pay attention to the needs of patients and serve them in the way they need, companies such as Dispenseroo will continue to drive the illicit market, preventing patients from accessing their medication in a legal way. 

This piece was written by Volteface Intern Megan Townsend. Megan is a current MA Criminology student at Birmingham City University. Tweets @megant2799.

The newsletter

The week in drugs and drug policy, in one email.

The newsletter opens soon. Follow the RSS feed in the meantime.